1
0
0
News
Oncolytics Biotech® Presents Clinical Data Supporting a Predictive ...www.theglobeandmail.com › ONCY-Q › pressreleases
www.theglobeandmail.com
· ... pelareorep to treatment-naïve, early-stage breast cancer patients," said Dr. Rita Laeufle, Chief Medical Officer of Oncolytics Biotech.
Oncolytics Biotech� Announces Appointment of Rita Laeufle, M.D., as...
article.wn.com
... currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Dr. Rita Laeufle, M.D., Ph.D., who ...
Biotech Brief: Why Oncolytic Viruses are Becoming a Potent Weapon...
www.finanznachrichten.de
PALM BEACH, Florida, March 24, PRNewswire/ -- Oncolytic viruses are becoming a new class of cancer immunotherapy weapons to combat cancer. These...
Imugene Limited gibt den Rücktritt von Rita Laeufle als Chief...
de.marketscreener.com
21. Jan · Imugene Limited gab eine Veränderung in einer Schlüsselposition des Managements bekannt. Dr. Rita Laeufle, Chief Medical Officer von Imugene, wird Ende Januar von ihrer Funktion und dem Unternehmen... | 10 Februar 2023
Interessen
At The ASCO: ONCY, IMV, CRDF, GILD, TAK… | Markets Insider
markets.businessinsider.com
· Commenting on the results, Rita Laeufle, Chief Medical Officer of Oncolytics Biotech, said, "The exciting clinical proof-of-concept data ...
[PPT] Download Figures (PPT) - The Lancetwww.thelancet.com › lanonc › article › PIIS (13)
www.thelancet.com
... Mahesh Parmar, DPhil, Rita Laeufle, MD, Young-Hyuck Im, MD, Gilles Romieu, MD, Vernon Harvey, MD, Oleg Lipatov, MD, Tadeusz Pienkowski, MD, Paul Cottu, ...
[PDF] Corporate Presentation - Seeking Alphastatic.seekingalpha.com › uploads › sa_presentations › original
static.seekingalpha.com
Rita Laeufle, MD, PhD. Chief Medical Officer. Clovis, Roche, Novartis. Kirk Look, CA. Chief Financial Officer. EY LLP. Andrew de Guttadauro.
Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data...
markets.businessinsider.com
Pre-clinical and clinical data demonstrate synergies between pelareorep and the proteasome inhibitor carfilzomib through inflammation, apoptosis a...
Business-Profile
Rita LAEUFLE | CMO | development | Research profile
www.researchgate.net
Rita Laeufle. Independent Researcher · development. Contact. Connect with experts in your field. Join ResearchGate to contact this researcher and connect with your scientific community. Join for ...
Eric Hufford Email & Phone Number - Phanes Ther..ZoomInfo
www.zoominfo.com
Rita Laeufle. Medical Chief & Advisor. Phone Email. Profile Picture. Jun Lu. Process Development & CMC Head. Phone Email.
Rita LAEUFLE | Genentech, California | Department of Medical...
www.researchgate.net
Rita LAEUFLE | Cited by 499 | of Genentech, California | Read 5 publications | Contact Rita LAEUFLE
Rita Laeufle Clovis Oncology · GMA San Francisco - ResearchGatewww.researchgate.net › Clovis Oncology
www.researchgate.net
Rita LAEUFLE, Senior Medical Director | Cited by 6 | of Clovis Oncology, Boulder | Read 2 publications | Contact Rita LAEUFLE.
Ausbildung
Rita Laeufle - BiographyMarket Screener
www.marketscreener.com
Portrait de Rita Laeufle. Rita Laeufle. Public asset : 686,028 USD ... Holdings of Rita Laeufle. Name, Equities, %, Valuation ... Rita Laeufle : Connections ...
Rita Laeufle - Biografie
ch.marketscreener.com
Currently, Rita Laeufle is Chief Medical Officer at Imugene Ltd.
In her past career Dr. Laeufle held the position of Chief Medical Officer of Oncolytics...
Rita Laeufle - Biografie - MarketScreener.com
de.marketscreener.com
Oder einloggen mit. Google Twitter
Bücher
Adjuvant bevacizumab-containing therapy in triple-negative breast...
www.infona.pl
... G Steger, Thomas M Suter, Masakazu Toi, Mahesh Parmar, Rita Laeufle, Young-Hyuck Im, Gilles Romieu, Vernon Harvey, ... Rita Laeufle.
– Page 4 - BioPubbiopub.co › author › supportthriveagency-com › page
biopub.co
Oncolytics Makes Good on Promise Brings New Tumor Response Biomarker to Clinic Oncolytics ($ONCY) CMO Rita Laeufle, MB, BCh likes Read more ...
Dokumente zum Namen
Imugene appoints Dr Rita Laeufle as Chief Medical OfficerSquarespace
static1.squarespace.com
Imugene appoints Dr Rita Laeufle as Chief Medical Officer. Sydney, Australia, 30 September 2020: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology.
[PDF] Imugene appoints Dr Rita Laeufle as Chief Medical Officerstatic1.squarespace.com › static › IMU+Rita+Laeufle+CMO
static1.squarespace.com
Sydney, Australia, 30 September 2020: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced the appointment of Dr Rita Laeufle, MD ...
Adjuvant bevacizumab-containing therapy in triple-negative 期刊界cnjournals.com › view_abstract
cnjournals.com
... Prof Masakazu Toi Mahesh Parmar Rita Laeufle Young-Hyuck Im Gilles Romieu Vernon Harvey Oleg Lipatov Tadeusz Pienkowski Paul Cottu Prof Arlene Chan Prof ...
Ohne Titelapps.asco.org › coidisplay › generateAbstractCOI
apps.asco.org
Rita Laeufle. Employment or Leadership Position - Genentech. Stock Ownership - Roche. Michelle Byrtek. Employment or Leadership Position - Genentech.
Veröffentlichungen allgemein
Biotech Dailywww.biotechdaily.com.au › uploads › › BD-Biotech-Daily-Jan-21
www.biotechdaily.com.au
IMUGENE LOSES CMO DR RITA LAEUFLE. MARKET REPORT. The Australian stock market tumbled percent on Friday January 21, 2022, with the.
NEW MEMBERSAmerican Association for Cancer Research
www.aacr.org
Rita Laeufle, MD, PhD. Imugene. United States. Active Member. Josh Laffin. Johns Hopkins University. United States. Associate Member. Bruna Morais Lage, BS.
[PDF] State of the Market Board and Executive Movements 28th ...blenheimpartners.com › wp-content › uploads ›
blenheimpartners.com
· Imugene Ltd: Dr Rita Laeufle has been appointed as Chief Medical Officer. • Kalium Lakes Ltd: Antony Beckmand has been appointed as Chief ...
Video & Audio
Imugene HER-Vaxx AACR Poster: Dr Rita Laeufle oral presentation...
www.youtube.com
Dr Rita Laeufle's presentation on Imugene's HER-Vaxx at AACR Learn more: imugene.com#HerVaxx #Immunotherapies #Imugene #ASX #Biotech
Artikel & Meinungen
Twitter-Nachrichten: Imugene - Twittertwitter.com › TeamImugene › status
· Today we've announced our Chief Medical Officer, Dr Rita Laeufle, will present on the HER-Vaxx cancer #immunotherapy program at the American ...
Groups | The Vault | Page
thevault.exchange
Stock exchange announcement alerts from South Africa, Nigeria and Ghana.
Oncolytics Biotech(R) Presents Biomarker Data in Second-line...
www.1stoncology.com
... immunoSEQ Assay to measure the diversity or clonality of the T cell population,” said Dr. Rita Laeufle, CMO of Oncolytics Biotech. ”Results ...
Oncolytics Biotech® Presents Biomarker Data in Second-line Pancreatic...
www.1stoncology.com
... with Adaptive Biotechnologies' immunoSEQ Assay to measure the diversity or clonality of the T cell population," said Dr. Rita Laeufle, CMO of ...
Sonstiges
Rita Laeufle Dr. - VP Clinical Development & Medical Affairs LinkedIn
www.linkedin.com
Sehen Sie sich das Profil von Rita Laeufle Dr. auf LinkedIn an, dem weltweit größten beruflichen Netzwerk. 6 Jobs sind im Profil von Rita Laeufle Dr. aufgelistet.
Rita Laeufle Dr. | LinkedIn
www.linkedin.com
View Rita Laeufle Dr.'s professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Rita Laeufle Dr. discover ...
Rita Laeufle | LinkedIn
www.linkedin.com
View Rita Laeufle's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Rita Laeufle discover inside ...
Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as ...
finance.yahoo.com
TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Dr. Rita Laeufle, M.D., Ph.D., ...
Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D.,...
ir.oncolyticsbiotech.com
CALGARY, Alberta and SAN DIEGO, Nov. 29, (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Dr. Rita Laeufle, M.D., Ph.D., who has been working as a consultant for Oncolytics for the last four months, has been appointed as Chief Medical Officer. Dr. Laeufle will oversee the clinical development plan for pelareorep as the company drives towards a registration ...
IMUGENE LIMITED (IUGNF) Company Profile & Factsfinance.yahoo.com › quote › IUGNF › profile
finance.yahoo.com
CFO & Joint Company Sec. N/A, N/A, Dr. Rita Laeufle M.D., Ph.D.
IMUGENE LIMITED (ASX:IMU) - Ann: Imugene appoints Dr Rita Laeufle as...
hotcopper.com.au
Imugene appoints Dr Rita Laeufle as Chief Medical Officer
finance.yahoo.com › news › oncolytics-biotech-r...Oncolytics Biotech(R) Announces Positive Yahoo Finance
finance.yahoo.com
... providing a strong scientific rationale regarding immune cell changes," said Dr. Rita Laeufle, Chief Medical Officer at Oncolytics Biotech.
Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as...
www.pm360online.com
... ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Dr. Rita Laeufle, M.D., Ph.D., ...
IMUGENE FPO (IMU.AX) company profile & facts – Yahoo Financeau.finance.yahoo.com › quote › IMU.AX › profile
au.finance.yahoo.com
Dr. Rita Laeufle M.D., Ph.D. Chief Medical Officer, N/A, N/A ...
Rita Laeufle Net Worth (2022) | wallmine
de.wallmine.com
1. Okt · Rita Laeufle biography. Dr. Rita Laeufle M.D., Ph.D. serves as Chief Medical Officer of the Company. As a board-certified surgical oncologist and a scientist, Dr Laeufle has extensive clinical development experience in immuno-oncology studies from Phase 1 to Phase 3 in breast and gastrointestinal cancers registration pathways. Dr ...
Oncolytics Biotech Inc. (ONCY) Company Profile & Facts ...ca.finance.yahoo.com › quote › ONCY › profile
ca.finance.yahoo.com
Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc, N/A, N/A, Dr. Rita Laeufle, Chief Medical Officer, N/A, N/A ...
Imugene Appoints Dr Rita Laeufle as its New Chief Medical Officer;...
kalkinemedia.com
Summary
Imugene has appointed Dr Rita Laeufle as its new Chief Medical Officer and a member of its executive leadership team.
Dr Laeufle will...
ONCOLYTICS BIOTECH INC (ONC.TO) Company Profile ...ca.finance.yahoo.com › quote › pr...
ca.finance.yahoo.com
Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc, k, N/A, Dr. Rita Laeufle, Chief Medical Officer ...
Proactive news headlines including Alchemy Resources ...
finance.yahoo.com
— ... to undergo a shift in personnel with the company's chief medical officer Dr Rita Laeufle retiring from her role at the end of January. › news
Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D. ...www.oncolyticsbiotech.com › press-releases › detail
www.oncolyticsbiotech.com
· Rita Laeufle, M.D., Ph.D., who has been working as a consultant for Oncolytics for the last four months, has been appointed as Chief Medical ...
Rita Laeufle, ESMO – Patient selection for touchONCOLOGYtouchoncology.com › Conference Hub
touchoncology.com
· In this interview, Dr Rita Laeufle tells us about the retrospective analysis of the Poseidon study, whereby patients with left-sided KRAS ...
Rita Laeufle [IMAGE] | EurekAlert! Science News Releaseswww.eurekalert.org › multimedia
www.eurekalert.org
Rita Laeufle is chief medical officer at Oncolytics Biotech, Inc. developing peloreorep, an IV-delivered immuno-oncolytic virus, and collaborating with ...
Rita Laeufle (ritalaeufle7) – Profil | Pinterest
www.pinterest.cl
Rita Laeufle. Follow. Rita Laeufle. 0 Followers. •. 2 Following. Rita Laeufle hasn't created any boards yet. Pinterest. Log in. Sign up. Privacy.
Breast Diseases: Laeufle, Rita - Expertscape.com
www.expertscape.com
Rita Laeufle has special expertise in Breast Diseases
Verwandte Suchanfragen zu Rita Laeufle
|
Personen Vorname "Rita" (23013) Name "Laeufle" (2) |
sortiert nach Relevanz / Datum